CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells - PubMed (original) (raw)
CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells
Rongcun Yang et al. Cancer Res. 2006.
Abstract
An elevated number of Gr-1+CD11b+ myeloid cells has been described in mice bearing transplantable tumors, and has been associated with immune suppression. We examined the role of such myeloid suppressor cells in mice bearing the spontaneously transformed syngeneic mouse ovarian surface epithelial cell line, 1D8. We observed high levels of CD80 expression by Gr-1+CD11b+ cells from spleen, ascites, and tumor tissue of mice bearing 1D8 ovarian carcinoma, whereas CD40 and CD86 were absent. CD80 expression was not detected on Gr-1+CD11b+ cells from naïve mice. However, the expression of CD80 by Gr-1+CD11b+ cells from naïve mice was promoted by coculture with 1D8 cells. Because irradiated 1D8 cells, but not 1D8-conditioned medium, up-regulate CD80 expression by Gr-1+CD11b+ cells, this phenomenon likely requires direct interaction. Gr-1+CD11b+ cells derived from 1D8 tumor-bearing mice provided significant suppression of antigen-specific immune responses, but Gr-1+CD11b+ cells from naïve mice did not. Both short interfering RNA-mediated knockdown and genetic knockout of CD80 expression by Gr-1+CD11b+ cells of 1D8 tumor-bearing mice alleviated the suppression of antigen-specific immune responses. Suppression via CD80 on Gr-1+CD11b+ myeloid cells was mediated by CD4+CD25+ T regulatory cells and required CD152. CD80 knockout or antibody blockade of either CD80 or CD152 retarded the growth of 1D8 tumor in mice, suggesting that expression of CD80 on Gr-1+CD11b+ myeloid cells triggered by 1D8 ovarian carcinoma suppresses antigen-specific immunity via CD152 signaling and CD4+CD25+ T regulatory cells. Thus, CD80-dependent responses to myeloid suppressor cells may contribute to tumor tolerance and the progression of ovarian carcinoma.
Comment in
- The terminology issue for myeloid-derived suppressor cells.
Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H. Gabrilovich DI, et al. Cancer Res. 2007 Jan 1;67(1):425; author reply 426. doi: 10.1158/0008-5472.CAN-06-3037. Cancer Res. 2007. PMID: 17210725 Free PMC article. No abstract available.
Similar articles
- B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer.
Liu Y, Zeng B, Zhang Z, Zhang Y, Yang R. Liu Y, et al. Clin Immunol. 2008 Dec;129(3):471-81. doi: 10.1016/j.clim.2008.07.030. Epub 2008 Sep 14. Clin Immunol. 2008. PMID: 18790673 - Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF.
Dolcetti L, Peranzoni E, Ugel S, Marigo I, Fernandez Gomez A, Mesa C, Geilich M, Winkels G, Traggiai E, Casati A, Grassi F, Bronte V. Dolcetti L, et al. Eur J Immunol. 2010 Jan;40(1):22-35. doi: 10.1002/eji.200939903. Eur J Immunol. 2010. PMID: 19941314 - Analysis of splenic Gr-1int immature myeloid cells in tumor-bearing mice.
Yamamoto Y, Ishigaki H, Ishida H, Itoh Y, Noda Y, Ogasawara K. Yamamoto Y, et al. Microbiol Immunol. 2008 Jan;52(1):47-53. doi: 10.1111/j.1348-0421.2008.00009.x. Microbiol Immunol. 2008. PMID: 18352913 - Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity.
Yamazaki S, Inaba K, Tarbell KV, Steinman RM. Yamazaki S, et al. Immunol Rev. 2006 Aug;212:314-29. doi: 10.1111/j.0105-2896.2006.00422.x. Immunol Rev. 2006. PMID: 16903923 Review. - Myeloid-derived suppressor cell heterogeneity and subset definition.
Peranzoni E, Zilio S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V. Peranzoni E, et al. Curr Opin Immunol. 2010 Apr;22(2):238-44. doi: 10.1016/j.coi.2010.01.021. Epub 2010 Feb 17. Curr Opin Immunol. 2010. PMID: 20171075 Review.
Cited by
- Proliferation of MDSCs may indicate a lower CD4+ T cell immune response in schistosomiasis japonica.
Peng B, Luo Y, Xie S, Zhuang Q, Li J, Zhang P, Liu K, Zhang Y, Zhou C, Guo C, Zhou Z, Zhou J, Cai Y, Xia M, Cheng K, Ming Y. Peng B, et al. Parasite. 2024;31:52. doi: 10.1051/parasite/2024050. Epub 2024 Aug 29. Parasite. 2024. PMID: 39212529 Free PMC article. - Immunosuppressive regulatory cells in cancer immunotherapy: restrain or modulate?
Wu Y, Chen D, Gao Y, Xu Q, Zhou Y, Ni Z, Na M. Wu Y, et al. Hum Cell. 2024 Jul;37(4):931-943. doi: 10.1007/s13577-024-01083-w. Epub 2024 May 30. Hum Cell. 2024. PMID: 38814516 Review. - Circadian control of tumor immunosuppression affects efficacy of immune checkpoint blockade.
Fortin BM, Pfeiffer SM, Insua-Rodríguez J, Alshetaiwi H, Moshensky A, Song WA, Mahieu AL, Chun SK, Lewis AN, Hsu A, Adam I, Eng OS, Pannunzio NR, Seldin MM, Marazzi I, Marangoni F, Lawson DA, Kessenbrock K, Masri S. Fortin BM, et al. Nat Immunol. 2024 Jul;25(7):1257-1269. doi: 10.1038/s41590-024-01859-0. Epub 2024 May 28. Nat Immunol. 2024. PMID: 38806707 Free PMC article. - Pivotal role of myeloid-derived suppressor cells in infection-related tumor growth.
Ito N, Tsujimoto H, Miyazaki H, Takahata R, Ueno H. Ito N, et al. Cancer Med. 2024 Feb;13(4):e6917. doi: 10.1002/cam4.6917. Cancer Med. 2024. PMID: 38457241 Free PMC article. - Delivery of Immunostimulatory Cargos in Nanocarriers Enhances Anti-Tumoral Nanovaccine Efficacy.
Schunke J, Mailänder V, Landfester K, Fichter M. Schunke J, et al. Int J Mol Sci. 2023 Jul 29;24(15):12174. doi: 10.3390/ijms241512174. Int J Mol Sci. 2023. PMID: 37569548 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials